Episode
Episode 70. ASH 2025 Myeloid Neoplasm Roundup with Dr. Curtis Lachowiez
- Podcast
- Blood Cancer Talks
- Published
- Feb 27, 2026
- Duration seconds
- 3413
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/71fb798f
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-70-ash-2025-myeloid-neoplasm-roundup-with-dr-curtis-lachowiez/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-70-ash-2025-myeloid-neoplasm-roundup-with-dr-curtis-lachowiez.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode, we dive deep into ASH 2025 updates on myeloid malignancies with Dr. Curtis Lachowiez. From the plenary halls of ASH 2025 to long-term follow-up of Aza/Ven/Gilteritinib, we unpack what the latest evidence means for the future of AML management. 1. PARADIGM Trial (Plenary Session, Abstract 6) Fathi A, Perl A, Fell G, et al. Results from PARADIGM – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood 2025;146(Suppl 1):6. https://doi.org/10.1182/blood-2025-6 ClinicalTrials.gov: NCT04801797 2. VICEROY Study – Aza/Ven/Gilteritinib Triplet (Abstract 654) Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy: Interim results from the phase 1/2 VICEROY study. Blood 2025;146(Suppl 1):654. ClinicalTrials.gov: NCT05520567 3. Long-Term Follow-Up of Aza/Ven/Gilteritinib in FLT3-Mutated AML (Abstract 45) Azevedo RS, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood 2025;146(Suppl 1):45. Original publication: Short NJ, Daver N, DiNardo CD, et al. J Clin Oncol 2024;42:1499–1508. https://doi.org/10.1200/JCO.23.01911 ClinicalTrials.gov: NCT04140487 4. PRISM-AML Score (Abstract 453) Lachowiez CA, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study. Blood 2025;146(Suppl 1):453. Interactive Calculator: https://prism-aml.com 5. Additional Studies Referenced in Discussion • VIALE-A Trial: DiNardo CD, et al. Azacitidine and venetoc…